SUBSCRIBE
SUBSCRIBE

Krystle Vermes

Drug Development
Medicago Kicks Off Phase I Trial for Plant-Derived COVID-19 Vaccine Candidate
It has already administered the first doses of the candidate in healthy human subjects, and the company intends to initiate a Phase II/III trial this coming October.
July 14, 2020
 · 
3 min read
 · 
Krystle Vermes
Business
Studies Suggest Blood Type May Impact the Severity of COVID-19 Cases
In general, studies have shown that people with Type O blood appear to be more protected than those with Type A, who are seemingly more vulnerable, according to NBC News.
July 13, 2020
 · 
2 min read
 · 
Krystle Vermes
Drug Development
Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS
Biogen announced on Wednesday that it has seen positive results from its Phase I/II study of tofersen, also known as BIIB067, for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
July 10, 2020
 · 
3 min read
 · 
Krystle Vermes
Forbion Continues Funding Efforts, Raises $208M for More Investments
Forbion, a European life sciences venture capital firm, announced today that it had closed its Forbion Growth Opportunities Fund at $208 million.
July 9, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Evive Biotech Sees Positive Results in Phase III Trial for CIN in Breast Cancer Patients
Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints.
July 8, 2020
 · 
3 min read
 · 
Krystle Vermes
Deals
Unum Therapeutics Forges Ahead with Acquisition of Kiq LLC
Unum Therapeutics announced on Monday that it has successfully completed its acquisition of Kiq LLC, a privately held biotechnology company with a focus on the discovery and development of precision kinase inhibitors.
July 7, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Immunomedics’ Trodelvy Successful in Phase III Breast Cancer Study
Immunomedics announced today that its Phase III study involving Trodelvy met its primary endpoint of progress-free survival, as well as secondary endpoints, in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies.
July 6, 2020
 · 
3 min read
 · 
Krystle Vermes
Biotech Bay
New Data Shows Promise Involving Lenacapavir for the Treatment of HIV
A study published in the journal Nature on July 1 suggests that there may be a new way to target an HIV protein called capsid, which was almost unmanageable in patients until now.
July 2, 2020
 · 
2 min read
 · 
Krystle Vermes
Genetown
Amylyx to Continue Pioneering New Treatments for Neurodegenerative Diseases with $30M in Funding
Massachusetts-based Amylyx Pharmaceuticals, a company focused on developing new treatments for neurodegenerative diseases, announced today that it had concluded a $30 million Series B round of financing.
July 2, 2020
 · 
3 min read
 · 
Krystle Vermes
Biotech Bay
Bolt Biotherapeutics Pushes Forward with Initiatives Following $93.5 Million Series C
Clinical-stage biotechnology company Bolt Biotherapeutics announced today that it has completed a $93.5 million Series C round of financing, led by Sofinnova Investments.
July 1, 2020
 · 
3 min read
 · 
Krystle Vermes
Deals
Report: Biotech IPOs Gave Healthcare Industry a Boost in Q2 2020
Specifically, the report indicated that biotechnology companies drove the healthcare industry to make up almost two-thirds of IPO activity in the second quarter of 2020.
June 29, 2020
 · 
2 min read
 · 
Krystle Vermes
BioNTech Receives More Funding on Its Path Toward a COVID-19 Vaccine
Clinical-stage biotechnology company BioNTech announced a private investment of $250 million today, led by Temasek and other investors.
June 29, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
New Data Shows 718 Pipeline Drugs Now Associated with COVID-19
New information released Tuesday by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19. In addition, 70% of these products are in the discovery or preclinical stages.
June 24, 2020
 · 
3 min read
 · 
Krystle Vermes
Deals
Poseida Therapeutics Forges Ahead with a Filing for $115M IPO
The company is focused on developing cell and gene therapies based on a proprietary DNA modification, gene editing and delivery technology.
June 23, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Recordati Announces Positive Phase III Results for ISTURISA in Cushing’s Patients
Specifically, the product was examined for its use in subjects where pituitary surgery is not an option or has not be curative.
June 18, 2020
 · 
3 min read
 · 
Krystle Vermes
Load More